Partilla, JS; Dempsey, AG; Nagpal, AS; Blough, BE; Baumann, MH; Rothman, RB. Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J. Pharmacol. Exp. Ther., 1 Oct 2006, 319 (1), 237–246. 367 kB. https://doi.org/10.1124/jpet.106.103622
Clarke, EGC. The identification of amphetamine type drugs. J. Forensic Sci. Soc., 1 Jan 1967, 7 (1), 31–36. 770 kB. https://doi.org/10.1016/S0015-7368(67)70368-0 #Phenmetrazine TLC
Banks, ML; Blough, BE; Fennell, TR; Snyder, RW; Negus, SS. Role of phenmetrazine as an active metabolite of phendimetrazine: Evidence from studies of drug discrimination and pharmacokinetics in rhesus monkeys. Drug Alcohol Depend., 1 Jun 2013, 130 (1–3), 158–166. 520 kB. https://doi.org/10.1016/j.drugalcdep.2012.10.026
Clarke, FH. cis- and trans-3-methyl-2-phenylmorpholine. J. Org. Chem., 1 Sep 1962, 27 (9), 3251–3253. 409 kB. https://doi.org/10.1021/jo01056a063 #V, X
McLaughlin, G; Morris, N; Kavanagh, PV; Dowling, G; Power, JD; Twamley, B; O’Brien, J; Talbot, B; Sitte, HH; Brandt, SD. Test purchase, synthesis and characterization of 3-fluorophenmetrazine (3-FPM) and differentiation from its ortho- and para-substituted isomers: Synthesis and characterization of fluorophenmetrazine positional isomers. Drug Test. Anal., 1 Mar 2017, 9 (3), 369-377. 1.3 MB. https://doi.org/10.1002/dta.1945 GC,MS,NMR,TLC,other
McLaughlin, G; Baumann, MH; Kavanagh, PV; Morris, N; Power, JD; Dowling, G; Twamley, B; O’Brien, J; Hessman, G; Westphal, F; Walther, D; Brandt, SD. Synthesis, analytical characterization and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta-positional isomers. Drug Test. Anal., 1 Sep 2018, 10 (9), 1404-1416. 20.6 MB. https://doi.org/10.1002/dta.2396 #Phenmetrazine
Calderon, SN; Klein, M. A regulatory perspective on the abuse potential evaluation of novel stimulant drugs in the United States. Neuropharmacology, 1 Dec 2014, 87, 97-103. 266 kB. https://doi.org/10.1016/j.neuropharm.2014.04.001
Biel, JH; Bopp, BA. Amphetamines: Structure-activity relationships. In Handbook of Psychopharmacology: Stimulants; Iversen, LL; Iversen, SD; Snyder, SH, Eds., Plenum Press, New York, 1 Jan 1978; pp 1–39. 1.0 MB. https://doi.org/10.1007/978-1-4757-0510-2_1
Thomä, O; Wick, H. Über einige Tetrahydro-1,4-oxazine mit sympathicomimetischen Eigenschaften. N-S. Arch. Pharmacol., 1 Nov 1954, 222 (6), 540-554. 1.6 MB. https://doi.org/10.1007/BF00246905 #A66
Holland, GF; Buck, CJ; Weissman, A. Anorexigenic agents: Aromatic substituted 1-phenyl-2-propylamines. J. Med. Chem., 1 Sep 1963, 6 (5), 519–524. 808 kB. https://doi.org/10.1021/jm00341a011 #Phenmetrazine
Nichols, DE. CNS Stimulants. In Burger's Medicinal Chemistry and Drug Discovery; Abraham, DJ, Ed., John Wiley & Sons, Inc., 29 Jan 2010; pp 89–120. 1.8 MB. https://doi.org/10.1002/0471266949.bmc243 #20
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #AP-005
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #F0 LC
Mellar, J; Hollister, LE. Phenmetrazine: An obsolete problem drug. Clin. Pharmacol. Ther., 1 Dec 1982, 32 (6), 671–675. 310 kB. https://doi.org/10.1038/clpt.1982.222 #Phenmetrazine
Mesley, RJ; Evans, WH. Infrared identification of some hallucinogenic derivatives of tryptamine and amphetamine. J. Pharm. Pharmacol., 1 May 1970, 22 (5), 321–332. 775 kB. https://doi.org/10.1111/j.2042-7158.1970.tb08533.x #Phenmetrazine IR
Canfield, DV; Lorimer, P; Epstein, RL. Gas chromatographic analysis of amphetamine derivatives and morpholine-related drugs. J. Forensic Sci., 1 Apr 1977, 22 (2), 429–433. 303 kB. https://doi.org/10.1520/JFS10605J #Phenmetrazine GC